Roche (RHHBY) Seeks $6.8 Billion Win on Heart Pill Where Pfizer Inc. (PFE) Failed
8/19/2011 8:09:41 AM
Roche Holding AG (ROG) may get the first signs at a cardiology conference this month that the Swiss drugmaker can garner $6.8 billion in sales with a pill to combat heart disease by raising so-called good cholesterol. The drug, dalcetrapib, may reap that much in annual revenue by 2020 if it works in patients who have had heart attacks, estimates Gbola Amusa, a UBS AG analyst in London. He gives the pill a one-in-four chance of succeeding. That’s by no means a sure thing. Basel, Switzerland-based Roche, known for cancer medicines such as Avastin and Herceptin, is venturing into a new area. The basic concept was dealt a setback in May when a study found an Abbott Laboratories (ABT) drug to raise good cholesterol didn’t prevent heart attacks. Pfizer Inc. (PFE) had to scrap its version in 2006 after patients died.
comments powered by